1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) (PLCB4)

Phospholipase C beta 4 (PLCB4) is a membrane-associated enzyme that plays a critical role in intracellular signal transduction by hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). This process, which requires calcium as a cofactor, is essential for G protein-coupled receptor (GPCR) signaling pathways, particularly in the retina and brain. PLCB4 is also vital for the proper development of the first and second pharyngeal arches, which form the head and face structures. In oncology, gain-of-function mutations in PLCB4, most notably the D630Y hotspot, act as oncogenic drivers in uveal melanoma by constitutively activating the GNAQ/GNA11 signaling pathway. Furthermore, PLCB4 overexpression or copy number gain is associated with poor prognosis and drug resistance in gastrointestinal stromal tumors (GIST) and acute myeloid leukemia (AML). Although no FDA-approved drugs currently target PLCB4 directly, it remains a significant candidate for therapeutic intervention in cancers driven by dysregulated G-protein signaling.

Other names

Phospholipase C-beta-4PLC-beta-4ARCND2PI-PLCPCL-C1

Inhibition of the PLC-beta-4 enzyme to block downstream calcium signaling and PKC activation, thereby inhibiting cell proliferation and survival in cancers driven by PLCB4 mutations or overexpression.